TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30575346
Drug: Photopheresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photopheresis with standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) for 10-15 sessions during the first 6 months after transplantation.
Study: 30575346
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) without photopheresis.
Study: 23926253
Drug: Cabergoline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (selective D2/D3 agonist)
Study: 20622414
Drug: Pharmacotherapy (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (Arm 4)
Study: 20622414
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education and behavioral therapy (not specified if part of the intervention arms)
Study: 14763194
Drug: Quinacrine pellets
Normalized name: quinacrine
DrugBank: Quinacrine (DB01103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinacrine pellets (252 mg total, 36 mg per pellet, three applications)
Study: 10944481
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (VA) intervention - 16,700 IU weekly
Study: 2940938
Drug: Midazolam (0.82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.82 mg/kg) plus Ketamine (2.0 mg/kg i.m.)
Study: 2940938
Drug: Diazepam (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (not specified dosage) plus Ketamine (2.0 mg/kg i.m.)
Study: 2940938
Drug: Ketamine (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2.4 mg/kg i.m. alone)
Study: 31558380
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including educational in-service, evidence-based tools for assessing neuropsychiatric symptoms, and monthly interprofessional team meetings
Study: 30589048
Drug: Chronomodulated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated chemotherapy (CC group) with cisplatin at 80 mg/m2 from 10:00 to 22:00 and 5-fluorouracil (5-FU) at 1000 mg/m2 plus citrovorum factor at 200 mg/m2 from 22:00 to 10:00 for 3 days.
Study: 30589048
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy (RC group) with cisplatin infusion within 1 h and 5-FU infusion for about 24 h, same dosage as CC group.
Study: 30589048
Drug: Chronomodulated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated chemotherapy (CC group)
Study: 30589048
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy (RC group)
Study: 25161021
Drug: Meropenem 1000mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1000mg, 30-minute infusion
Study: 25161021
Drug: Meropenem 500mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500mg, 3-hour infusion
Study: 15904635
Drug: Rosuvastatin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin at 10 mg
Study: 15904635
Drug: Atorvastatin, pravastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, pravastatin, and simvastatin
Study: 9728642
Drug: Paroxetine (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (initially 20 mg, flexible dosing up to 50 mg/d)
Study: 8158888
Drug: Protein-restricted diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-restricted diet (0.4 g per kg)
Study: 759617
Drug: Alphaprodine 0.135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphaprodine 0.135 mg/kg
Study: 759617
Drug: Alphaprodine 0.270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphaprodine 0.270 mg/kg
Study: 759617
Drug: Meperidine 0.564
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.564 mg/kg
Study: 759617
Drug: Meperidine 1.127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1.127 mg/kg
Study: 24511708
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg day(‐1))
Study: 21483189
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal at 200 ml/day (trial group)
Study: 21483189
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal at 150 ml/day (control group)
Study: 9596205
Drug: DZP rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZP rectal gel (15 mg)
Study: 9596205
Drug: Intravenous DZP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous DZP (7.5 mg)
Study: 7850397
Drug: True electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: True electroconvulsive therapy (ECT)
Study: 11571237
Drug: ALT‐711 (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALT‐711 (210 mg)
Study: 21410446
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of drugs added to a participant's medication regimen during the 1‐year study period
Study: 19628217
Drug: T‐cell receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐cell receptor excision circles (TRECs) quantification using neonatal Guthrie cards
Study: 8454796
Drug: Solidified benzyl
Normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solidified benzyl benzoate and tenside agents (A)
Study: 3961072
Drug: Alcohol group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol group, drinking .08 ml of pure alcohol per kg body weight
Study: 18574364
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg b.i.d. from day 1 to 3, 300 mg q.i.d. from day 4 to 6, and 600 mg t.i.d. from day 7 to 10)
Study: 15906167
Drug: Talinolol in
Normalized name: talinolol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol in fast-disintegrating capsules with food
Study: 15906167
Drug: Talinolol in
Normalized name: talinolol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol in enteric-coated capsules
Study: 15906167
Drug: Talinolol in
Normalized name: talinolol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol in rectal capsules
Study: 12641984
Drug: Glutamine dipeptide
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine dipeptide (0.5 g/kg/day, orally in bolus)
Study: 10426876
Drug: IIb-IIIa platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb-IIIa platelet receptor antagonists
Study: 30819157
Drug: Removing drug
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removing drug mark-ups
Study: 30819157
Drug: Removing drug
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removing drug markups
Study: 18984393
Drug: Mini-implants (miniplates,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants (miniplates, miniscrews, or microscrews)
Study: 18984393
Drug: Traditional anchorage
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional anchorage preparation with a transpalatal arch and headgear
Study: 18984393
Drug: Mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants
Study: 10235220
Drug: 10 million
Normalized name: Interferon Alfa-2b 10 MILLION IU/1 ML Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 million units alpha-N1 IFN i.m. t.w. for 24 wk (total dose: 720 million units)
Study: 1859007
Drug: ORG9426 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG9426 0.12 mg/kg
Study: 1859007
Drug: ORG9426 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG9426 0.16 mg/kg
Study: 1859007
Drug: ORG9426 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG9426 0.20 mg/kg
Study: 1859007
Drug: ORG9426 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG9426 0.6 mg/kg (group 1)
Study: 1859007
Drug: ORG9426 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG9426 0.6 mg/kg (group 2)
Study: 6353523
Drug: L-tryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (1 g)
Study: 22677260
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone
Study: 22677260
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone and Risedronate (DR) 30 mg oral once daily
Study: 12296840
Drug: Various cancer
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various cancer treatments; specific interventions not detailed; focus on quality of life measures using standardized schedules.
Study: 9806651
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone or in combination with radiation for regional disease
Study: 9806651
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for distant disease
Study: 1659438
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naloxone
Study: 24078028
Drug: Continuous intradermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intradermal sutures
Study: 23034962
Drug: Dietary phylloquinone
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary phylloquinone intake (100 μg phylloquinone/d)
Study: 15465973
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.1 mg/kg)
Study: 15465973
Drug: High-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketamine (0.5 mg/kg)
Study: 8076620
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (50 g at time 0 min and 25 g at time 60 and 120 min)
Study: 25881462
Drug: Yiqi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huoxue Decoction (YHD), one dose daily for 14 days
Study: 25881462
Drug: Routine symptomatic
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine symptomatic treatment (Group A)
Study: 20564681
Drug: Analgesic
Normalized name: Analgesic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic
Study: 15139072
Drug: Tibetan yoga
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tibetan yoga (TY) intervention, 7 weekly yoga sessions
Study: 11339516
Drug: diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 150 mg
Study: 8432915
Drug: rIFN-gamma (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma (50 micrograms/m2 daily subcutaneous injection for 12 weeks)
Study: 31711704
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CoQ10/kg diet
Study: 31711704
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CoQ10/kg diet
Study: 31711704
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg CoQ10/kg diet (Control)
Study: 27015659
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (4-month moderate- to hard-intensity exercise training programme, 29 one-hour classes, twice weekly)
Study: 24072136
Drug: Innovator drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator drug (Omnipaque)
Study: 24072136
Drug: Generic drug
Normalized name: CELECOXIB 200 mg ORAL CAPSULE [Generic drug]
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic drug (Iopaque)
Study: 21902684
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus dexamethasone (low or high doses)
Study: 18239240
Drug: Herbal supplement
Normalized name: LYDIA PINKHAM Herbal Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplement
Study: 10942063
Drug: Bendamustine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 80 mg/m2
Study: 10942063
Drug: Bendamustine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 60 mg/m2
Study: 10942063
Drug: Bendamustine 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 70 mg/m2
Study: 10942063
Drug: Bendamustine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (all doses)
Study: 8782844
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg twice a day)
Study: 1619943
Drug: MMC 12
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 12 mg/m2 intravenously on day 1 and OK‐432 5 KE intradermally on days 6, 8, and 11
Study: 1619943
Drug: MMC 12
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 12 mg/m2 alone followed by long‐term tegafur
Study: 30470229
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d combined with ezetimibe 10 mg/d (A20E10 group, n=48)
Study: 30470229
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d (A40 group, n=50)
Study: 27798770
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg SOFE (50 mg hydroxytyrosol)
Study: 27798770
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg SOFE (100 mg hydroxytyrosol)
Study: 18250251
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride (100 mg) with medical management (MM) alone
Study: 18250251
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride (100 mg) with combined behavioral intervention (CBI)
Study: 10216805
Drug: Eprosartan (200‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (200‐300 mg b.i.d.)
Study: 10216805
Drug: Enalapril (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5‐20 mg o.d.)
Study: 8801328
Drug: Dilapress 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 240 (formulation A) single dose (240 mg)
Study: 8801328
Drug: Dilapress 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 240 (formulation A) multiple dose (240 mg qd for 6 days)
Study: 8801328
Drug: Cardizem CD
Normalized name: Cardizem CD
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardizem CD (formulation B)
Study: 8801328
Drug: Dilapress 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 240 (formulation A) single dose (240 mg) without subject 8
Study: 8801328
Drug: Dilapress 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapress 240 (formulation A) and Cardizem CD (formulation B)
Study: 2196146
Drug: Dextroamphetamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (up to 1.5 mg/kg/day)
Study: 2196146
Drug: Methylphenidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (up to 3.0 mg/kg/day)
Study: 31103
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg oral dose before anaesthesia
Study: 31310855
Drug: Apixaban plus
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban plus aspirin
Study: 31310855
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (apixaban, thienopyridine, and aspirin)
Study: 31310855
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (apixaban plus aspirin)
Study: 24107881
Drug: Psychosocial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial group therapy (PST) for 3 months
Study: 24107881
Drug: Psychosocial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial group therapy (PST)
Study: 20209977
Drug: Acupuncture-assisted anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-assisted anesthesia (AAA) group: electroacupuncture (EA, 2 Hz/100 Hz, 9 mA) applied to Changqiang (GV 1) and Yaoshu (GV 2) for 20 min, and 1% lidocaine (5 mL) injected into GV 1.
Study: 20209977
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 20 mL and 10 mL of 1% lidocaine injected into GV 2 and GV 1, respectively.
Study: 8001520
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of slow release ascorbic acid, 100 micrograms of organic selenium, 200 mg of D‐alpha‐tocopheryl acetate and 30 mg of beta‐carotene daily for 3 months
Study: 3042874
Drug: Dexamethasone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (initial dose, 3 mg/kg; total, 11.4 mg/kg per 48 h)
Study: 30915444
Drug: Higher intake
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intake of lutein plus zeaxanthin (L + Z)
Study: 28370447
Drug: Dextromethorphan/quinidine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan/quinidine (45 mg/10 mg twice daily)
Study: 21740445
Drug: Gamma irradiation
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma irradiation (60 Gy in daily increments of 2 Gy)
Study: 16607109
Drug: Ultralow-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow-dose transdermal estradiol at 0.014 mg/d
Study: 14682655
Drug: Oxalate desensitizing
Normalized name: oxalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalate desensitizing agent
Study: 10953672
Drug: Cereal-based foods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal-based foods (chapatti, idli, poori) containing 50 g carbohydrate
Study: 10953672
Drug: Reference glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference glucose load (50 g)
Study: 8363067
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia followed by intravenous morphine (GA)
Study: 3539618
Drug: Metoprolol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 15 mg i.v. + 50 mg q.i.d. orally
Study: 1837931
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nebulized ipratropium bromide
Study: 1837931
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nebulized ipratropium bromide
Study: 1837931
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline (5 mg) administered 2 hours after ipratropium
Study: 22044044
Drug: Oral antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidants (AOs) treatment with α‐lipoic acid at 400 mg/day in association with genistein and vitamins
Study: 19387424
Drug: Atomoxetine (0.5‐1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5‐1.8 mg/kg per day)
Study: 12903414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without drugs)
Study: 9233529
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 on day 1 and oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Study: 9233529
Drug: Paclitaxel 160
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 160 mg/m2 on day 5 (schedule B)
Study: 9233529
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 on day 1 with oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Study: 1345132
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (50 units/kg IV immediately after antivenom, followed by continuous infusion of 10 units/kg/hour for 24 hours)
Study: 3549872
Drug: Piracetam 2
Normalized name: piracetam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2 X 3 g
Study: 3549872
Drug: Piracetam 2
Normalized name: piracetam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2 X 12 g
Study: 30329199
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug (0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine)
Study: 25042199
Drug: Siltuximab (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (11 mg/kg intravenous infusion every 3 weeks)
Study: 22397837
Drug: High-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol chocolate containing maltitol (266 mg)
Study: 22397837
Drug: High-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol chocolate with sucrose (251 mg)
Study: 22397837
Drug: Low-flavanol chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol chocolate with sucrose (48 mg)
Study: 18245199
Drug: Atrial pacing
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON
Study: 18245199
Drug: Atrial pacing
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF
Study: 18245199
Drug: Atrial pacing
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON with septal lead placement
Study: 18245199
Drug: Atrial pacing
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF with septal lead placement